{"database": "openregs", "table": "documents", "is_view": false, "human_description_en": "where docket_id = \"FDA-2009-D-0137\" sorted by posted_date descending", "rows": [["FDA-2009-D-0137-0045", "FDA", "FDA-2009-D-0137", "Use of Serological Tests to Reduce the Risk of Transmission of  Trypanosoma cruzi Infection in Blood and Blood Components; Guidance for Industry; Availability", "Notice", "Notice of Availability", "2017-12-06T05:00:00Z", 2017, 12, "2017-12-06T05:00:00Z", null, "2017-12-06T15:20:12Z", "2017-26226", 0, 0, "0900006482ce90a2"], ["FDA-2009-D-0137-0046", "FDA", "FDA-2009-D-0137", "Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Blood and Blood Components Guidance for Industry", "Other", "Guidance", "2017-12-06T05:00:00Z", 2017, 12, "2017-12-06T05:00:00Z", null, "2024-11-07T01:13:38Z", null, 1, 0, "0900006482ce9dc0"], ["FDA-2009-D-0137-0028", "FDA", "FDA-2009-D-0137", "Amendment to Guidance for Industry: Use of Serological Tests To Reduce\nthe Risk of Transmission of Trypanosoma cruzi Infection in Whole Blood and Blood Components Intended for Transfusion; Draft Guidance for Industry; Availability", "Notice", "Notice of Availability", "2016-11-10T05:00:00Z", 2016, 11, "2016-11-10T05:00:00Z", "2017-02-09T04:59:59Z", "2017-02-07T02:02:05Z", "2016-27107", 0, 0, "0900006482387508"], ["FDA-2009-D-0137-0036", "FDA", "FDA-2009-D-0137", "Reference 7 Donors deferred for self-reported Chagas disease history:\ndoes it reduce risk?", "Supporting & Related Material", "Background Material", "2016-11-10T05:00:00Z", 2016, 11, null, null, "2016-11-10T15:31:11Z", null, 0, 0, "09000064823877ec"], ["FDA-2009-D-0137-0031", "FDA", "FDA-2009-D-0137", "Reference 2-Autochthonous Transmission of Trypanosoma cruzi, Louisiana", "Supporting & Related Material", "Background Material", "2016-11-10T05:00:00Z", 2016, 11, null, null, "2016-11-10T15:30:56Z", null, 0, 0, "0900006482387a72"], ["FDA-2009-D-0137-0038", "FDA", "FDA-2009-D-0137", "Reference 9 Trypanosoma cruzi (E. coli Recombinant) Antigen ABBOTT PRISM Chagas Package Insert (2010)", "Supporting & Related Material", "Background Material", "2016-11-10T05:00:00Z", 2016, 11, null, null, "2016-11-10T15:31:17Z", null, 0, 0, "09000064823877ee"], ["FDA-2009-D-0137-0029", "FDA", "FDA-2009-D-0137", "Amendment to \u201cGuidance for Industry: Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Whole Blood and Blood Components Intended for Transfusion\u201d", "Other", "Guidance", "2016-11-10T05:00:00Z", 2016, 11, "2016-11-10T05:00:00Z", "2017-02-09T04:59:59Z", "2024-11-12T06:15:55Z", null, 1, 0, "0900006482387a6f"], ["FDA-2009-D-0137-0039", "FDA", "FDA-2009-D-0137", "Reference 10  FDA Blood Products Advisory Committee T. cruzi Incidence Study in Blood Donors and its Implications for One-time Testing of Blood Donors August 2 2011", "Supporting & Related Material", "Background Material", "2016-11-10T05:00:00Z", 2016, 11, null, null, "2016-11-10T15:31:20Z", null, 0, 0, "09000064823877ef"], ["FDA-2009-D-0137-0042", "FDA", "FDA-2009-D-0137", "Reference 13 Trypanosoma cruzi (E coli) Recombinant Antigen ABBOTT ESA Chagas Package Insert 2011", "Supporting & Related Material", "Background Material", "2016-11-10T05:00:00Z", 2016, 11, null, null, "2016-11-10T15:31:29Z", null, 0, 0, "09000064823877f2"], ["FDA-2009-D-0137-0035", "FDA", "FDA-2009-D-0137", "Reference 6-Epidemiology of American Trypanosomiasis (Chagas Disease)", "Supporting & Related Material", "Background Material", "2016-11-10T05:00:00Z", 2016, 11, null, null, "2016-11-10T15:31:08Z", null, 0, 0, "09000064823877eb"], ["FDA-2009-D-0137-0037", "FDA", "FDA-2009-D-0137", "Reference 8 Trypanosoma cruzi (T cruzi) Whole Cell Lysate Antigen ORTHO T cruzi ELISA Test System Package Insert 2009", "Supporting & Related Material", "Background Material", "2016-11-10T05:00:00Z", 2016, 11, null, null, "2016-11-10T15:31:15Z", null, 0, 0, "09000064823877ed"], ["FDA-2009-D-0137-0032", "FDA", "FDA-2009-D-0137", "Reference 3-Case Report: Evidence of Autochthonous Chagas Disease in Southeastern Texas", "Supporting & Related Material", "Background Material", "2016-11-10T05:00:00Z", 2016, 11, null, null, "2016-11-10T15:30:58Z", null, 0, 0, "0900006482387a73"], ["FDA-2009-D-0137-0033", "FDA", "FDA-2009-D-0137", "Reference 4-An Estimate of the Burden of Chagas Disease in the United States", "Supporting & Related Material", "Background Material", "2016-11-10T05:00:00Z", 2016, 11, null, null, "2016-11-10T15:31:02Z", null, 0, 0, "0900006482387a74"], ["FDA-2009-D-0137-0034", "FDA", "FDA-2009-D-0137", "Reference 5-Trypanosoma cruzi infection in North America and Spain:\nevidence in support of transfusion transmission", "Supporting & Related Material", "Background Material", "2016-11-10T05:00:00Z", 2016, 11, null, null, "2016-11-10T15:31:05Z", null, 0, 0, "09000064823877ea"], ["FDA-2009-D-0137-0040", "FDA", "FDA-2009-D-0137", "Reference 11 FDA Blood Products Advisory Committee Reentry of blood donors deferred on the basis of screening test results for antibodies to T. cruzi July 31 2014", "Supporting & Related Material", "Background Material", "2016-11-10T05:00:00Z", 2016, 11, null, null, "2016-11-10T15:31:23Z", null, 0, 0, "09000064823877f0"], ["FDA-2009-D-0137-0030", "FDA", "FDA-2009-D-0137", "AMENDMENT TO \u201cGUIDANCE FOR INDUSTRY: USE OF SEROLOGICAL TESTS TO REDUCE THE RISK OF TRANSMISSION OF TRYPANOSOMA CRUZI INFECTION IN WHOLE BLOOD AND BLOOD COMPONENTS INTENDED FOR TRANSFUSION\u201d DRAFT GUIDANCE FOR INDUSTRY", "Supporting & Related Material", "Background Material", "2016-11-10T05:00:00Z", 2016, 11, null, null, "2016-11-10T15:30:52Z", null, 0, 0, "0900006482387a71"], ["FDA-2009-D-0137-0041", "FDA", "FDA-2009-D-0137", "Reference 12 FDA Blood Products Advisory Committee Potential Testing Strategies for T. cruzi Infection in Blood Donors April 1 2009", "Supporting & Related Material", "Background Material", "2016-11-10T05:00:00Z", 2016, 11, null, null, "2016-11-10T15:31:26Z", null, 0, 0, "09000064823877f1"], ["FDA-2009-D-0137-0027", "FDA", "FDA-2009-D-0137", "Guidance for Industry Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Whole Blood and Blood Components Intended for Transfusion", "Other", "Guidance", "2010-12-06T05:00:00Z", 2010, 12, "2010-12-06T05:00:00Z", null, "2024-11-07T22:30:35Z", null, 1, 0, "0900006480bafc56"], ["FDA-2009-D-0137-0025", "FDA", "FDA-2009-D-0137", "Agency Information Collection Activities; Proposals, Submissions, and Approvals: Guidance for Industry; Use of Serological Tests to Reduce Risk of Transmission of Trypanosoma cruzi Infection, etc.", "Notice", "30 Day Proposed Information Collection", "2010-12-06T05:00:00Z", 2010, 12, "2010-12-06T05:00:00Z", "2011-01-06T04:59:59Z", "2016-10-28T18:34:06Z", "2010-30404", 0, 0, "0900006480bafe83"], ["FDA-2009-D-0137-0026", "FDA", "FDA-2009-D-0137", "Guidance for Industry: Use of Serological Tests to Reduce Riskof Transmission of Trypanosoma cruzi Infection, etc.", "Notice", "Notice of Availability", "2010-12-06T05:00:00Z", 2010, 12, "2010-12-06T05:00:00Z", null, "2016-10-28T18:39:30Z", "2010-30405", 0, 0, "0900006480baff0b"], ["FDA-2009-D-0137-0011", "FDA", "FDA-2009-D-0137", "Tab 27 - PubMed Results - \"Chagas Disease & The U. S. Blood Supply\"  - Reference [re FDA-2009-D-0137-0002]", "Supporting & Related Material", "REF-Reference (internal unless indicated)", "2009-04-10T04:00:00Z", 2009, 4, null, null, "2009-04-10T16:00:00Z", null, 0, 0, "090000648092ff9e"], ["FDA-2009-D-0137-0009", "FDA", "FDA-2009-D-0137", "Reference 26 - \"Guidance for Industry: Biological Product Deviation Reporting for Blood and Plasma Establishments, October 2006\" - [re FDA-2009-D-0137-0002]", "Supporting & Related Material", "REF-Reference (internal unless indicated)", "2009-03-30T04:00:00Z", 2009, 3, null, null, "2011-06-29T19:45:14Z", null, 0, 0, "090000648092ff42"], ["FDA-2009-D-0137-0010", "FDA", "FDA-2009-D-0137", "Reference 29 - \"FDA Blood Products Advisory Committee Meeting, September 12, 2002\" - [re FDA-2009-D-0137-0002]", "Supporting & Related Material", "REF-Reference (internal unless indicated)", "2009-03-30T04:00:00Z", 2009, 3, null, null, "2011-06-29T19:49:33Z", null, 0, 0, "090000648092ffba"], ["FDA-2009-D-0137-0006", "FDA", "FDA-2009-D-0137", "Reference 15 -  CDC/MMWR , \"Chagas Disease After Organ Transplantation - Los Angeles, California, 2006\" - [re FDA-2009-D-0137-0002]", "Supporting & Related Material", "REF-Reference (internal unless indicated)", "2009-03-30T04:00:00Z", 2009, 3, null, null, "2011-06-29T19:37:58Z", null, 0, 0, "090000648092fd18"], ["FDA-2009-D-0137-0005", "FDA", "FDA-2009-D-0137", "Reference 14 - CDC/MMWR , \"Chagas Disease After Organ Transplantation - United States, 2001\" - [re FDA-2009-D-0137-0002]", "Supporting & Related Material", "REF-Reference (internal unless indicated)", "2009-03-30T04:00:00Z", 2009, 3, null, null, "2011-06-29T19:35:35Z", null, 0, 0, "090000648092fd07"], ["FDA-2009-D-0137-0007", "FDA", "FDA-2009-D-0137", "Reference 24 - CDC/MMWR, \"Blood Donor Screening for Chagas Disease - United States, 2006-2007\" - [re FDA-2009-D-0137-0002]", "Supporting & Related Material", "REF-Reference (internal unless indicated)", "2009-03-30T04:00:00Z", 2009, 3, null, null, "2011-06-29T19:39:42Z", null, 0, 0, "090000648092ff2c"], ["FDA-2009-D-0137-0008", "FDA", "FDA-2009-D-0137", "Reference 25 - \"FDA Blood Products Advisory Committee, 89th Meeting, April 27, 2007 (Concept Paper)\" - [re FDA-2009-D-0137-0002]", "Supporting & Related Material", "REF-Reference (internal unless indicated)", "2009-03-30T04:00:00Z", 2009, 3, null, null, "2011-06-29T19:43:30Z", null, 0, 0, "090000648092ff3a"], ["FDA-2009-D-0137-0004", "FDA", "FDA-2009-D-0137", "Reference 1 - \"Guidance for Industry: Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps), August 2007\" - [re FDA-2009-D-0137-0002]", "Supporting & Related Material", "REF-Reference (internal unless indicated)", "2009-03-29T04:00:00Z", 2009, 3, null, null, "2011-06-29T19:14:36Z", null, 0, 0, "090000648092fa11"], ["FDA-2009-D-0137-0002", "FDA", "FDA-2009-D-0137", "Guidance for Industry - Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Whole Blood and Blood Components for Transfusion and Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) - Guidance", "Other", "Guidance", "2009-03-26T04:00:00Z", 2009, 3, "2009-03-26T04:00:00Z", null, "2011-06-29T17:49:54Z", null, 0, 0, "0900006480930814"], ["FDA-2009-D-0137-0003", "FDA", "FDA-2009-D-0137", "Table of Contents - References [re FDA-2009-D-0137-0002]", "Supporting & Related Material", "REF-Reference (internal unless indicated)", "2009-03-26T04:00:00Z", 2009, 3, null, null, "2011-06-29T19:10:28Z", null, 0, 0, "0900006480931787"], ["FDA-2009-D-0137-0001", "FDA", "FDA-2009-D-0137", "Draft Guidance for Industry: Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Whole Blood and Blood Components for Transfusion and Human Cells, Tissues, and Cellular and Tissue-Based Products", "Notice", "NAD-Notice of Availability of Data", "2009-03-26T04:00:00Z", 2009, 3, "2009-03-26T04:00:00Z", "2009-06-25T03:59:59Z", "2011-06-29T17:38:37Z", "E9-06684", 0, 0, "0900006480930640"]], "truncated": false, "filtered_table_rows_count": 31, "expanded_columns": [], "expandable_columns": [[{"column": "docket_id", "other_table": "dockets", "other_column": "id"}, "title"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "units": {}, "query": {"sql": "select id, agency_id, docket_id, title, document_type, subtype, posted_date, posted_year, posted_month, comment_start_date, comment_end_date, last_modified, fr_doc_num, open_for_comment, withdrawn, object_id from documents where \"docket_id\" = :p0 order by posted_date desc limit 101", "params": {"p0": "FDA-2009-D-0137"}}, "facet_results": {"agency_id": {"name": "agency_id", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2009-D-0137", "results": [{"value": "FDA", "label": "FDA", "count": 31, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2009-D-0137&agency_id=FDA", "selected": false}], "truncated": false}, "document_type": {"name": "document_type", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2009-D-0137", "results": [{"value": "Supporting & Related Material", "label": "Supporting & Related Material", "count": 22, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2009-D-0137&document_type=Supporting+%26+Related+Material", "selected": false}, {"value": "Notice", "label": "Notice", "count": 5, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2009-D-0137&document_type=Notice", "selected": false}, {"value": "Other", "label": "Other", "count": 4, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2009-D-0137&document_type=Other", "selected": false}], "truncated": false}, "posted_year": {"name": "posted_year", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2009-D-0137", "results": [{"value": 2016, "label": 2016, "count": 15, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2009-D-0137&posted_year=2016", "selected": false}, {"value": 2009, "label": 2009, "count": 11, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2009-D-0137&posted_year=2009", "selected": false}, {"value": 2010, "label": 2010, "count": 3, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2009-D-0137&posted_year=2010", "selected": false}, {"value": 2017, "label": 2017, "count": 2, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2009-D-0137&posted_year=2017", "selected": false}], "truncated": false}}, "suggested_facets": [{"name": "subtype", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2009-D-0137&_facet=subtype"}, {"name": "posted_date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2009-D-0137&_facet=posted_date"}, {"name": "posted_month", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2009-D-0137&_facet=posted_month"}, {"name": "comment_start_date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2009-D-0137&_facet=comment_start_date"}, {"name": "comment_end_date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2009-D-0137&_facet=comment_end_date"}, {"name": "open_for_comment", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2009-D-0137&_facet=open_for_comment"}, {"name": "posted_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2009-D-0137&_facet_date=posted_date"}, {"name": "comment_start_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2009-D-0137&_facet_date=comment_start_date"}, {"name": "comment_end_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2009-D-0137&_facet_date=comment_end_date"}, {"name": "last_modified", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2009-D-0137&_facet_date=last_modified"}], "next": null, "next_url": null, "private": false, "allow_execute_sql": true, "query_ms": 844.4127150578424, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}